Your browser doesn't support javascript.
loading
A novel CD8+ T cell-related gene signature as a prognostic biomarker in hepatocellular carcinoma.
Peng, Xiaozhen; Lu, Xingjun; Yang, Daqing; Liu, Jinyan; Wu, Honglin; Peng, Hong; Zhang, Yiya.
Affiliation
  • Peng X; School of Public Health & Laboratory Medicine, Hunan University of Medicine, Huaihua, China.
  • Lu X; Hunan Provincial Key Laboratory for Synthetic Biology of Traditional Chinese Medicine, Hunan University of Medicine, Huaihua, China.
  • Yang D; School of Public Health & Laboratory Medicine, Hunan University of Medicine, Huaihua, China.
  • Liu J; School of Public Health & Laboratory Medicine, Hunan University of Medicine, Huaihua, China.
  • Wu H; Hunan Normal University, Changsha, China.
  • Peng H; School of Public Health & Laboratory Medicine, Hunan University of Medicine, Huaihua, China.
  • Zhang Y; Medical School, Huanghe Science & Technology College, Zhengzhou, China.
Medicine (Baltimore) ; 103(11): e37496, 2024 Mar 15.
Article de En | MEDLINE | ID: mdl-38489709
ABSTRACT
CD8+ T cells have great roles in tumor suppression and elimination of various tumors including hepatocellular carcinoma (HCC). Nonetheless, potential prognostic roles of CD8+ T cell-related genes (CD8Gs) in HCC remains unknown. In our study, 416 CD8Gs were identified in HCC, which were enriched in inflammatory and immune signaling pathways. Using The Cancer Genome Atlas dataset, a 5-CD8Gs risk model (KLRB1, FYN, IL2RG, FCER1G, and DGKZ) was constructed, which was verified in International Cancer Genome Consortium and gene expression omnibus datasets. Furthermore, we found that overall survival was independently correlated with the CD8Gs signature, and it was associated with immune- and cancer-related signaling pathways and immune cells infiltration. Finally, drug sensitivity data indicated that 10 chemotherapeutic drugs held promise as therapeutics for HCC patients with high-risk. In conclusion, multi-databases analysis showed that 5-CD8Gs and their signature could be an indicator to predict candidate drugs for HCC therapy.
Sujet(s)

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Carcinome hépatocellulaire / Tumeurs du foie Limites: Humans Langue: En Journal: Medicine (Baltimore) Année: 2024 Type de document: Article Pays d'affiliation: Chine Pays de publication: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Carcinome hépatocellulaire / Tumeurs du foie Limites: Humans Langue: En Journal: Medicine (Baltimore) Année: 2024 Type de document: Article Pays d'affiliation: Chine Pays de publication: États-Unis d'Amérique